NewAmsterdam Pharma (NAMS) Cash from Operations (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Cash from Operations of 30604000.0 for Q1 2026, up 16.08% on a YoY basis from 26364610.03 in Q1 2025, and up 25.13% sequentially from 40875000.0 in Q4 2025.
NewAmsterdam Pharma (NAMS) Cash from Operations (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Cash from Operations data on file, last reported at 30604000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 16.08% year-over-year to 30604000.0; the trailing twelve-month figure through Mar 2026 stood at 141919000.0 (down 1.06% YoY), and the FY2025 full-year result was 147783000.0, up 6.8% from the prior year.
- Cash from Operations climbed to 30604000.0 in Q1 2026, from 40875000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 12502000.0 in Q3 2024 to a low of 54602000.0 in Q1 2024.
- A 4-year average of 36782230.77 and a median of 36468000.0 in 2025 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations jumped 73.39% in 2024 and tumbled 162.11% in 2025, its largest moves.
- Tracing NAMS's Cash from Operations over 4 years: stood at 33074000.0 in 2023, then retreated by 13.32% to 37481000.0 in 2024, then decreased by 9.06% to 40875000.0 in 2025, then rose by 25.13% to 30604000.0 in 2026.
- Business Quant data shows NAMS's Cash from Operations at 30604000.0 in Q1 2026, 40875000.0 in Q4 2025, and 32769000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -30.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.60 Mn |
| Mar 31, 2026 | -30.60 Mn |
| Dec 31, 2025 | -40.88 Mn |
| Dec 31, 2025 | -40.88 Mn |
| Sep 30, 2025 | -32.77 Mn |
| Sep 30, 2025 | -32.77 Mn |
| Jun 30, 2025 | -37.67 Mn |
| Jun 30, 2025 | -37.67 Mn |
| Mar 31, 2025 | -36.47 Mn |
| Mar 31, 2025 | -36.47 Mn |
| Dec 31, 2024 | -37.48 Mn |
| Dec 31, 2024 | -37.48 Mn |
| Sep 30, 2024 | -12.50 Mn |
| Sep 30, 2024 | -12.50 Mn |
| Jun 30, 2024 | -53.98 Mn |
| Jun 30, 2024 | -53.98 Mn |
| Mar 31, 2024 | -54.60 Mn |
| Mar 31, 2024 | -54.60 Mn |
| Dec 31, 2023 | -33.07 Mn |
| Dec 31, 2023 | -33.07 Mn |